CN216221894U - Novel esophageal mitomycin drug eluting stent - Google Patents
Novel esophageal mitomycin drug eluting stent Download PDFInfo
- Publication number
- CN216221894U CN216221894U CN202121894598.5U CN202121894598U CN216221894U CN 216221894 U CN216221894 U CN 216221894U CN 202121894598 U CN202121894598 U CN 202121894598U CN 216221894 U CN216221894 U CN 216221894U
- Authority
- CN
- China
- Prior art keywords
- mitomycin
- nickel
- silica gel
- titanium alloy
- layer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 229930192392 Mitomycin Natural products 0.000 title claims abstract description 37
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 title claims abstract description 37
- 229960004857 mitomycin Drugs 0.000 title claims abstract description 37
- 239000003814 drug Substances 0.000 title claims abstract description 35
- 229940079593 drug Drugs 0.000 title claims abstract description 24
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims abstract description 35
- 239000000741 silica gel Substances 0.000 claims abstract description 35
- 229910002027 silica gel Inorganic materials 0.000 claims abstract description 35
- 229910001000 nickel titanium Inorganic materials 0.000 claims abstract description 30
- 239000011248 coating agent Substances 0.000 claims abstract description 10
- 238000000576 coating method Methods 0.000 claims abstract description 10
- 229920006237 degradable polymer Polymers 0.000 claims description 6
- 230000008961 swelling Effects 0.000 claims description 5
- 229910045601 alloy Inorganic materials 0.000 claims description 4
- 239000000956 alloy Substances 0.000 claims description 4
- 238000010828 elution Methods 0.000 claims description 3
- 238000000151 deposition Methods 0.000 claims description 2
- 229920001296 polysiloxane Polymers 0.000 claims 2
- 208000031481 Pathologic Constriction Diseases 0.000 abstract description 2
- 210000003238 esophagus Anatomy 0.000 description 9
- 206010030194 Oesophageal stenosis Diseases 0.000 description 4
- 210000002950 fibroblast Anatomy 0.000 description 4
- 229910052751 metal Inorganic materials 0.000 description 4
- 239000002184 metal Substances 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 208000007217 Esophageal Stenosis Diseases 0.000 description 3
- 206010072208 Oesophageal fibrosis Diseases 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 230000004761 fibrosis Effects 0.000 description 3
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 2
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 2
- 206010016654 Fibrosis Diseases 0.000 description 2
- 206010058522 Oesophageal injury Diseases 0.000 description 2
- 230000006907 apoptotic process Effects 0.000 description 2
- 230000004900 autophagic degradation Effects 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 210000002744 extracellular matrix Anatomy 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 208000018380 Chemical injury Diseases 0.000 description 1
- 238000012323 Endoscopic submucosal dissection Methods 0.000 description 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 1
- 206010062575 Muscle contracture Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- HZEWFHLRYVTOIW-UHFFFAOYSA-N [Ti].[Ni] Chemical compound [Ti].[Ni] HZEWFHLRYVTOIW-UHFFFAOYSA-N 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 208000006111 contracture Diseases 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000012326 endoscopic mucosal resection Methods 0.000 description 1
- 201000004101 esophageal cancer Diseases 0.000 description 1
- 208000021302 gastroesophageal reflux disease Diseases 0.000 description 1
- 230000017525 heat dissipation Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000002324 minimally invasive surgery Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000003973 paint Substances 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 239000004814 polyurethane Substances 0.000 description 1
- 229920002635 polyurethane Polymers 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 208000037803 restenosis Diseases 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 229910001285 shape-memory alloy Inorganic materials 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
Images
Landscapes
- Media Introduction/Drainage Providing Device (AREA)
- Materials For Medical Uses (AREA)
Abstract
The utility model relates to a novel esophageal mitomycin drug eluting stent, which belongs to the technical field of esophageal stents and comprises a nickel-titanium alloy net rack, wherein an external silica gel layer is fixedly arranged on the outer wall of the nickel-titanium alloy net rack, and an internal silica gel layer is fixedly arranged on the inner wall of the nickel-titanium alloy net rack. The mitomycin and the silica gel coating of 0.4mg/ml are coated on the nickel-titanium alloy memory bracket, so that the lumen is supported, the esophageal fibroplasia is resisted, and the esophageal benign stricture can be prevented or treated.
Description
Technical Field
The utility model relates to the technical field of esophageal stents, in particular to a novel esophageal mitomycin drug eluting stent.
Background
Benign stricture of esophagus is esophageal contracture caused by chronic non-tumor esophageal injury and fibrosis due to various reasons, and the main reasons include corrosive injury, injury after radiotherapy, long-term gastroesophageal reflux, stricture of anastomotic stoma after esophageal surgery and more esophageal injuries after endoscopic minimally invasive surgery in recent years. With the improvement of the screening and diagnosis technology of early esophageal cancer in recent years, esophageal stenosis after endoscopic mucosal resection and endoscopic submucosal dissection is more common in clinic.
At present, the esophageal stents mainly applied in clinical use are mainly classified into metal stents and bioabsorbable stents. The metal stent is divided into a bare metal stent, a semi-covered stent and a full-covered stent, the bare stent is made of nickel-titanium memory alloy, and the surface of the bare stent is usually coated with a layer of coating, such as polyurethane or silica gel. The stent for treating esophageal stenosis is an esophageal full-coating stent, but the stent and the coating can only play a physical supporting role and cannot inhibit the progress of esophageal fibrosis, so that the esophageal stent still has the possibility of restenosis after being taken out.
SUMMERY OF THE UTILITY MODEL
The utility model provides a novel esophageal mitomycin drug eluting stent, which solves the problems in the background technology.
The scheme for solving the technical problems is as follows: novel esophagus mitomycin medicine elution support, including nickel titanium alloy rack, the outer wall fixed mounting of nickel titanium alloy rack has external silica gel layer, the inner wall fixed mounting of nickel titanium alloy rack has built-in silica gel layer, the inner wall on built-in silica gel layer is close to top edge through connection and has the entry rack, the inner wall fixed mounting of entry rack has the alloy crotch, the inner wall on built-in silica gel layer is close to top edge fixed mounting and has the go-between, the inner wall swivelling joint of go-between has the check-back board, the bottom fixed mounting of check-back board has the silica gel ball, deposit the medicine layer has been seted up to the inside on external silica gel layer, and the inner wall of depositing the medicine layer has scribbled the mitomycin layer near one side of nickel titanium alloy rack.
On the basis of the technical scheme, the utility model can be further improved as follows.
Furthermore, the top and the bottom of the mitomycin layer are both provided with degradable polymer drug-loaded layers.
Further, the outer wall of the external silica gel layer is provided with a medicine coating hole.
Further, the mitomycin layer was set at a concentration of 0.4 mg/ml.
Further, the top and bottom edges of the external silica gel layer and the internal silica gel layer are fixedly connected.
Further, the nickel-titanium alloy net rack is of a structure with two expanded ends, the length of the expanded structure is 10mm, and the diameter of the expanded structure is 22 mm.
Further, the diameter of the middle section of the nickel-titanium alloy net rack is set to be 20 mm.
The utility model provides a novel esophageal mitomycin drug eluting stent, which has the following advantages:
mitomycin is added into common bracket film-coated material silica gel to achieve the effect of slow release, the slow release mitomycin can continuously promote apoptosis and autophagy of esophageal fibroblasts on the premise of supporting by a metal bracket, and the secretion of extracellular matrix of the esophageal fibroblasts is inhibited, so that the process of esophageal fibrosis is accelerated, 0.4mg/ml mitomycin and a silica gel coating are coated on a nickel-titanium alloy memory bracket to achieve the effect of supporting a lumen and resisting esophageal fibroplasia, and the preparation method can be used for preventing or treating benign esophageal stenosis.
The foregoing description is only an overview of the technical solutions of the present invention, and in order to make the technical solutions of the present invention more clearly understood and to implement them in accordance with the contents of the description, the following detailed description is given with reference to the preferred embodiments of the present invention and the accompanying drawings. The detailed description of the present invention is given in detail by the following examples and the accompanying drawings.
Drawings
The accompanying drawings, which are included to provide a further understanding of the utility model and are incorporated in and constitute a part of this application, illustrate embodiment(s) of the utility model and together with the description serve to explain the utility model without limiting the utility model. In the drawings:
FIG. 1 is a schematic structural diagram of a novel esophageal mitomycin drug-eluting stent according to one embodiment of the present invention;
FIG. 2 is a schematic structural diagram of a drug-loaded layer of a degradable polymer in the novel esophageal mitomycin drug-eluting stent provided by an embodiment of the present invention;
FIG. 3 is a schematic structural view of a heat dissipation frame in the novel esophageal mitomycin drug elution stent provided by an embodiment of the present invention;
fig. 4 is a front view of the novel esophageal mitomycin drug-eluting stent provided by an embodiment of the present invention.
In the drawings, the components represented by the respective reference numerals are listed below:
1. a nickel-titanium alloy net frame; 2. an external silica gel layer; 3. a silica gel layer is arranged inside; 4. an entrance net rack; 5. an alloy hook; 6. a connecting ring; 7. a check plate; 8. a silica gel ball; 9. a mitomycin layer; 10. a degradable polymeric drug-loaded layer; 11. and (4) coating the medicine holes.
Detailed Description
The principles and features of the present invention are described below in conjunction with the accompanying fig. 1-4, which are provided by way of example only to illustrate the present invention and not to limit the scope of the present invention. The utility model is described in more detail in the following paragraphs by way of example with reference to the accompanying drawings. Advantages and features of the present invention will become apparent from the following description and from the claims. It is to be noted that the drawings are in a very simplified form and are not to precise scale, which is merely for the purpose of facilitating and distinctly claiming the embodiments of the present invention.
It will be understood that when an element is referred to as being "secured to" another element, it can be directly on the other element or intervening elements may also be present. When a component is referred to as being "connected" to another component, it can be directly connected to the other component or intervening components may also be present. When a component is referred to as being "disposed on" another component, it can be directly on the other component or intervening components may also be present. The terms "vertical," "horizontal," "left," "right," and the like as used herein are for illustrative purposes only.
Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. The terminology used in the description of the utility model herein is for the purpose of describing particular embodiments only and is not intended to be limiting of the utility model. As used herein, the term "and/or" includes any and all combinations of one or more of the associated listed items.
As shown in fig. 1-4, novel esophageal mitomycin drug eluting stent, including nickel-titanium alloy rack 1, nickel-titanium alloy rack 1's outer wall fixed mounting has external silica gel layer 2, nickel-titanium alloy rack 1's inner wall fixed mounting has built-in silica gel layer 3, built-in silica gel layer 3's inner wall is close to top edge through connection and has entry rack 4, entry rack 4's inner wall fixed mounting has alloy crotch 5, built-in silica gel layer 3's inner wall is close to top edge fixed mounting has go-between 6, go-between 6's inner wall swivelling joint has check board 7, the bottom fixed mounting of check board 7 has silica gel ball 8, the medicine layer has been seted up in external silica gel layer 2's inside and has been deposited, and deposit the one side that the inner wall of medicine layer is close to nickel-titanium alloy rack 1 and has been paintd mitomycin layer 9.
Preferably, the top and the bottom of the mitomycin layer 9 are both provided with degradable polymer drug-loaded layers 10, so that the mitomycin layer 9 is prevented from leaking too quickly to influence the treatment effect.
Preferably, the outer wall of the external silica gel layer 2 is provided with a drug coating hole 11, so that the drug on the inner wall of the mitomycin layer 9 can slowly seep out through the drug coating hole 11.
Preferably, the mitomycin layer 9 is provided at a concentration of 0.4mg/ml, with 0.4mg/ml mitomycin enabling more effective and safe fibrosis within the esophagus.
Preferably, the top and bottom edges of the external silica gel layer 2 and the internal silica gel layer 3 are fixedly connected, so that the nickel-titanium alloy net rack 1 cannot be exposed inside the esophagus.
Preferably, nickel titanium alloy rack 1 sets up to the both ends structure of swelling, and the structure length of swelling is 10mm, the diameter is 22mm, is convenient for stably block equipment at the esophagus inner wall.
Preferably, the diameter of the middle section of the nickel-titanium alloy net rack 1 is set to be 20mm, so that food can enter smoothly.
The specific working principle and the using method of the utility model are as follows: the length of nickel-titanium alloy rack 1 sets up according to pathological change position length, the structure of swelling of both sides can be with equipment card at the esophagus inner wall, the inside of external silica gel layer 2 is provided with mitomycin layer 9 and degradable polymer drug-loaded layer 10, make mitomycin layer 9 evenly paint the inner wall at the esophagus through scribbling medicine hole 11 after degradable polymer drug-loaded layer 10 degrades, under the prerequisite that nickel-titanium alloy rack 1 supported, the mitomycin of slow release can continuously promote the apoptosis of esophagus fibroblast, autophagy, it secretes extracellular matrix to restrain esophagus fibroblast, thereby impel the process of esophagus fibrosis, improve treatment effeciency.
The foregoing is merely a preferred embodiment of the utility model and is not intended to limit the utility model in any manner; the present invention may be readily implemented by those of ordinary skill in the art as illustrated in the accompanying drawings and described above; however, those skilled in the art should appreciate that they can readily use the disclosed conception and specific embodiments as a basis for designing or modifying other structures for carrying out the same purposes of the present invention without departing from the scope of the utility model as defined by the appended claims; meanwhile, any changes, modifications, and evolutions of the equivalent changes of the above embodiments according to the actual techniques of the present invention are still within the protection scope of the technical solution of the present invention.
Claims (6)
1. Novel esophageal mitomycin medicine elution support comprises a nickel-titanium alloy net rack (1) and is characterized in that: the utility model discloses a nickel-titanium alloy net rack, including nickel-titanium alloy net rack (1), the outer wall fixed mounting of nickel-titanium alloy net rack (1) has external silica gel layer (2), the inner wall fixed mounting of nickel-titanium alloy net rack (1) has built-in silica gel layer (3), the inner wall of built-in silica gel layer (3) is close to top edge through connection has entry net rack (4), the inner wall fixed mounting of entry net rack (4) has alloy crotch (5), the inner wall of built-in silica gel layer (3) is close to top edge fixed mounting has go-between (6), the inner wall swivelling joint of go-between (6) has check board (7), the bottom fixed mounting of check board (7) has silica gel ball (8), the medicine layer has been seted up to the inside of external silica gel layer (2), and the one side that the inner wall of depositing the medicine layer is close to nickel-titanium alloy net rack (1) has been paintd mitomycin layer (9).
2. The novel esophageal mitomycin drug eluting stent according to claim 1, characterized in that both the top and the bottom of the mitomycin layer (9) are provided with a degradable polymer drug carrying layer (10).
3. The novel esophageal mitomycin drug eluting stent according to claim 1, wherein the outer wall of the external silica gel layer (2) is provided with drug coating holes (11).
4. The novel esophageal mitomycin drug eluting stent according to claim 1, characterized in that the top and bottom edges of the external silicone layer (2) and the internal silicone layer (3) are fixedly connected.
5. The novel esophageal mitomycin drug eluting stent according to claim 1, characterized in that the nickel-titanium alloy mesh frame (1) is provided with a swelling structure at both ends, the swelling structure has a length of 10mm and a diameter of 22 mm.
6. The novel esophageal mitomycin drug eluting stent according to claim 1, characterized in that the diameter of the middle section of the nickel-titanium alloy mesh frame (1) is set to 20 mm.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202121894598.5U CN216221894U (en) | 2021-08-13 | 2021-08-13 | Novel esophageal mitomycin drug eluting stent |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202121894598.5U CN216221894U (en) | 2021-08-13 | 2021-08-13 | Novel esophageal mitomycin drug eluting stent |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN216221894U true CN216221894U (en) | 2022-04-08 |
Family
ID=80980505
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202121894598.5U Expired - Fee Related CN216221894U (en) | 2021-08-13 | 2021-08-13 | Novel esophageal mitomycin drug eluting stent |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN216221894U (en) |
-
2021
- 2021-08-13 CN CN202121894598.5U patent/CN216221894U/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1649551B (en) | Drug-delivery endovascular stent and method for treating restenosis | |
| CN104857570A (en) | Degradable zinc-based alloy bracket and preparation method thereof | |
| CN102772831A (en) | Degradable drug loading stent | |
| JP2006519623A (en) | Vascular stent or vascular graft coated or impregnated with protein tyrosine kinase inhibitor and method of use thereof | |
| CN108261275A (en) | Bioabsorbable stent | |
| CN101632606A (en) | Interventional medical device carrying medicaments | |
| JP2014531933A (en) | Intervention medical device and manufacturing method thereof | |
| EP2581099B1 (en) | Intervention medical device and preparation thereof | |
| CN108289747A (en) | Bioabsorbable holder | |
| Pan et al. | Recent advances in surface endothelialization of the magnesium alloy stent materials | |
| JP2014530058A (en) | Intervention medical device and manufacturing method thereof | |
| CN216221894U (en) | Novel esophageal mitomycin drug eluting stent | |
| CN101181650B (en) | Bracket for controlling releasing and elution of tranilast medicament coating | |
| CN201055442Y (en) | Novel blood vessel support | |
| CN100400113C (en) | Preparation method of metal support surface micro blind hole drug-loaded layer | |
| Ebrahimi-Nozari et al. | Multimodal effects of asymmetric coating of coronary stents by electrospinning and electrophoretic deposition | |
| CN107913119A (en) | A kind of interventional medical device and preparation method thereof | |
| CN101239216A (en) | Novel sacculus dilating catheter | |
| CN102018996A (en) | Manufacturing method of drug vessel support with antibody immobilized on surface of support | |
| CN106618818A (en) | Woven vascular drug stent | |
| EP3639830B1 (en) | Composite anti-restenosis drug for coronary drug-eluting stent, and controlled release system thereof | |
| CN202740163U (en) | Cardiovascular medicament coating rack | |
| CN100413540C (en) | Gene carrying rack and its producing method and use | |
| CN100435755C (en) | Bracket for eluting medication | |
| Feng et al. | Development history of endovascular surgery and devices |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20220408 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |